Deputy Editor Philippa Harris talks to Lise Jamieson (Health Economics and Epidemiology Research Office, University of Witswatersrand, South Africa) and Gesine Mayer-Rath (Health Economics and Epidemiology Research Office and the University of Boston, USA) about cost-effectiveness of long-acting cabotegravir for PrEP in South Africa. Read the full article: Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
